Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fr receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?,TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Abstract: The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.

Abstract: The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.

Abstract: Compositions and methods for the treatment and diagnosis of cancer are disclosed.

Abstract: Methods for treating tumors comprise contacting tumor cells expressing the vitamin D receptor with a vitamin D receptor ligand that inhibits homologous recombination in the tumor cells, and contacting the tumor cells with an amount of a Poly(ADP) Ribose Polymerase 1 (PARP-1) inhibitor. Inhibiting homologous recombination produces a synergistic therapeutic effect between the vitamin D receptor ligand and PARP-1 inhibitor, and may overcome PARP-1 resistance in killing tumor cells.

Abstract: RNA virus vectors comprising a gene encoding the DNA-dependent activator of interferon-regulatory factors (DAI) protein, and optionally further comprising a gene encoding the receptor-interacting serine/threonine-protein kinase 3 (RIPK3) may be used therapeutically to induce cell death, as well as an inflammatory immune response, against tumors and virally-infected cells.

Abstract: Methods for generating hybrid antibodies are provided.

Abstract: An apparatus and method are provided for positioning a patient on a surgical platform. The apparatus includes an elongated flexible web and a plurality of extension straps for connecting the apparatus to the surgical platform. Each extension strap includes a connector configured for connecting the apparatus to the platform. Adjustment mechanisms allow the extension straps to be adjusted to vary the tension in the web. The medical professional selects the desired position and orientation of the patient on the surgical platform and manipulates the patient into the desired position and orientation. A retention device is connected to a surgical platform and placed over the patient at the appropriate portion of the patient. A second end of the retention device is connected to a second side of the surgical platform. The retention device is then adjusted to increase the tension in the retention device.

Abstract: An apparatus is provided, which utilizes an adjustment platform for supporting a subject during the endoscopic examination. Additionally, a method for performing an endoscopic examination is also provided in which an endoscope is inserted into a subject and the endoscope is maintained at a generally fixed position while the position of the subject is adjusted to advance the endoscope into the subject. Further still, a method is provided for estimating the size of sample tissue using an endoscope and a reference element. Based on known parameters of the reference element, the size of the area being examined can be estimated.

Abstract: The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.

Abstract: Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed.

Abstract: The invention relates to methods of inhibiting the growth or proliferation of a cell, the method comprising reducing the expression or activity of at least one gene in the cell selected from the group consisting of BLOC1S1, CDC2L1, CNOT1, CYR61, DDX54, EIF3I, FANCG, FBP1, IER2, KIF1A, LCK, NR2F1, PNRC1, POLR2A, POLR2B, POLR2C, PRPF6, PSMB4, PSMC5, PSMD1, PTK7, RPS2, SCNN1A, SF3A3, TAF2, TOB1, TSC22D4.

Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?,TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

Abstract: Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.

Abstract: Disclosed are devices that comprise a protein, such as an antibody, placed into electronic communication with a semiconductor material, such as a carbon nanotube. The devices are useful in assessing the presence or concentration of analytes contacted to the devices, including the presence of markers for prostate cancer and Lyme disease.

Abstract: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.

Abstract: The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.

Abstract: Treating Sonic Hedgehog-Associated Medulloblastoma comprises inhibiting the synthesis or biologic activity of leukotrienes that drive Nestin expression in cancerous or precancerous granule neuron precursors and that further drive growth and proliferation of medulloblastoma cells through Nestin-mediated aberrant Sonic Hedgehog signaling.